IN THE CLAIMS:

1-17. (Canceled)

18. (Currently amended) A vaccine composition, comprising:

a Streptococcus suis mutant deficient in capsular expression, wherein the Streptococcus suis mutant comprises a mutation eausing the deficiency in a sequence selected from the group consisting of SEQ ID NO: 9, SEQ ID NO: 29, SEQ ID NO: 37 and SEQ ID NO: 43; eapsular expression is stable and

a pharmaceutically acceptable carrier or adjuvant.

19-20. (Canceled)

- 21. (Currently amended) The <u>vaccine</u> composition of claim 18, wherein said *Streptococcus suis* mutant deficient in capsular expression is capable of surviving in an immune-competent host.
- 22. (Currently amended) The <u>vaccine composition</u> of claim 21, wherein said *Streptococcus suis* mutant deficient in capsular expression is capable of surviving at least 4-5 days in said immune-competent host.
- 23. (Currently amended) The <u>vaccine_composition_of claim 18</u>, wherein said *Streptococcus suis* mutant deficient in capsular expression expresses a *Streptococcus* virulence factor or antigenic determinant.
- 24. (Currently amended) The <u>vaccine-composition</u> of claim 18, wherein said *Streptococcus suis* mutant deficient in capsular expression expresses a non-*Streptococcus* protein.
- 25. (Currently amended) The <u>vaccine_composition_of claim 24</u>, wherein said non-*Streptococcus* protein has been derived from a pathogen.

26-31. (Canceled)

32. (Currently amended) The vaccine composition of claim 21, wherein said Streptococcus suis mutant has been produced by homologous recombination.

6 C 113

33. (Currently amended) The <u>vaccine_composition_of_claim_21</u>, wherein said Streptococcus suis mutant is capable of surviving at least 8-10 days in said host.

34-37. (Canceled)

38. (Currently amended) The <u>vaccine_composition</u> of claim 22, wherein said *Streptococcus suis* mutant deficient in capsular expression expresses a *Streptococcus* virulence factor or antigenic determinant.

39-49. (Canceled)

50. (Currently amended) The <u>vaccine</u> <u>composition</u> of claim 38, wherein said Streptococcus suis mutant deficient in capsular expression expresses a non-Streptococcus protein.

51-52. (Canceled)

- 53. (Currently amended) The vaccine composition of claim—52 18, wherein the stable mutation comprises a knock-out in the capsular gene cluster sequence.
- 54. (Currently amended) The vaccine composition of claim 52 18, wherein the mutation comprises a mutated cpsB gene, a mutated cpsEF gene, or a combination thereof.
- 55. (Currently amended) The vaccine composition of claim 52 18, wherein the Streptococcus suis eell expresses a non-Streptococcal protein.

56-57. (Canceled)